Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher ...

Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and ...

In the first quarter, lower sales of multiple sclerosis (“MS”) drugs are likely to have been offset by revenues from new drugs. Sales of Biogen’s MS drugs like Tecfidera and Tysabri are ...